This article focuses on clinical applications of T cells transduced to express recombinant T cell receptor and chimeric antigen receptor constructs directed toward hematological malignancies, and considers newer strategies incorporating gene-editing technologies to address GvHD and host-mediated rejection. Recent data from clinical trials are reviewed, and an overview is provided of current and emerging manufacturing processes; consideration is also given to new developments in the pipeline.
Key points
- •
T cells engineered with chimeric antigen receptors mediate high levels of leukemic remission.
- •
Emerging gene editing techniques are now being incorporated.
- •
Challenges for dissemination to a larger number of patients are being addressed.
Related posts:
Gene Therapy
Historical Perspective on the Current Renaissance for Hematopoietic Stem Cell Gene Therapy
Therapeutic Gene Editing Safety and Specificity
Opening Marrow Niches in Patients Undergoing Autologous Hematopoietic Stem Cell Gene Therapy
Gene Therapy Approaches to Hemoglobinopathies
Gene Therapy for Hemophilia
Stay updated, free articles. Join our Telegram channel
Full access? Get Clinical Tree
